Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan
Schoenen, Jean; Pascual, J.; Rasmussen, S.et al.
2005 • In European Journal of Neurology, 12 (2), p. 108-117
[en] This current randomized, open-label, crossover study evaluated preference for oral eletriptan 80 mg compared with subcutaneous sumatriptan 6 mg (suma-sc) amongst patients (n = 311) meeting IHS criteria for migraine who had recently used suma-sc, and found it well tolerated. Three attacks were treated on each study medication. Assessment of subjective preference was evaluated, after which patients freely chose which study medication they wished to use to treat each of three additional migraine attacks. A slight majority (50.6%) preferred or greatly preferred eletriptan, whilst 43% preferred suma-sc. When permitted to choose between eletriptan and suma-sc for subsequent treatment, 78% of patients who had preferred eletriptan took eletriptan during the extension phase for all three of their attacks, whilst only 37% of patients who preferred suma-sc took suma-sc for all of their extension-phase attacks (P < 0.05). Secondary efficacy measures showed comparable efficacy for each study medication, except for faster headache response and pain-free rates favor of suma-sc, and a significantly lower recurrence rate on eletriptan (25% vs. 40%; P < 0.05). The results of this study suggest that eletriptan is a strong alternative option for patients who have been prescribed suma-sc.
Disciplines :
Neurosciences & behavior Neurology
Author, co-author :
Schoenen, Jean ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie
Pascual, J.
Rasmussen, S.
Sun, W.
Sikes, C.
Hettiarachchi, J.
Language :
English
Title :
Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan
Bouchard J, Cortelli P, Dahlof C et al. (1997). A multinational investigation of the impact of subcutaneous sumatriptan. IV: Patient satisfaction. Pharmacoeconomics 11(Suppl. 1):43-50.
Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr (1991). Treatment of acute migraine with subcutaneous sumatriptan. JAMA 265:2831-2935.
Dahlöf C (2001). Assessing patient preference in migraine treatment. Cephalalgia 21:791-795.
Davies GM, Santanello NC, Kramer M, Matzure-Wolfe D (1998). Determinants of patient satisfaction with migraine treatment. Headache 38:174 (abstract).
Davis KH, Black L, Sleath B (2002). Validation of the Patient Perception of Migraine questionnaire. Value Health 5:421-429.
Dodick D (2002). Patient perceptions and treatment preferences in migraine management. CNS Drugs 16(Suppl. 1): 19-24.
Goadsby PJ, Ferrari MD, Olesen J et al. (2000), Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. Neurology 54:156-163.
Headache Classification Committee of the International Headache Society (1988). Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8(Suppl. 7):1-96.
Lipton RB, Hamelsky SW, Dayno JM (2002). What do patients with migraine want from acute migraine treatment? Headache 42(Suppl. 1):3-9.
MacGregor EA (1997). The doctor and the migraine patient: improving compliance. Neurology 48(Suppl. 3):S16-S20.
Mathew NT, Schoenen J, Winner P, Muirhead N, Sikes CR (2003). Comparative efficacy of eletriptan 40 mg vs. sumatriptan 100 mg. Headache 43:214-222.
Oldman AD, Smith LA, McQuay HJ, Moore RA (2002). Pharmacological treatments for acute migraine: quantitative systematic review. Pain 97:247-257.
Perry CM, Markham A (1998). Sumatriptan. An updated review of its use in migraine. Drugs 55:889-922.
Sandrini G, Farkkila M, Burgess G, Forster E, Haughie S, for the Eletriptan Steering Committee (2002). Eletriptan vs. sumatriptan: a double-blind, placebo-controlled multiple migraine attack study. Neurology 59:1210-1217.
Sheftell FD, Fox AW (2000). Acute migraine treatment outcome measures. A clinician's view. Cephalalgia 20(Suppl. 2): 14-24.
Silberstein SD (1995). Migraine symptoms: results of a survey of self-reported migraineurs. Headache 35:387-396.